Novai founder Francesca Cordeiro discusses DARC technology, AI diagnostics, and commercialization plans for eye disease detection
Summary
Host Susannah Streeter interviews Novai founder Francesca Cordeiro about DARC technology, which uses a fluorescent dye and AI to detect stressed cells in the eye for early disease diagnosis. Cordeiro explains that the technology allows pharmaceutical companies to determine drug efficacy in weeks during Phase 1/2 trials, significantly reducing development timelines. She highlights a £60 billion market opportunity in geographic atrophy and notes that Novai has raised nearly £6 million in non-dilutive funding from sources like the Wellcome Trust and Innovate UK. The company is currently pre-Series A, seeking funding to bridge the gap to commercialization and validate its AI through upcoming US pivotal trials. Cordeiro also discusses the potential for a future nasal spray version of the dye to enable high-street screening.
Key takeaways
- 1 Novai contrasts its single-cell level detection with competitors like Google DeepMind, which operates at a structural tissue level.
Unidentified speaker (speaker_1) · 26:44
- 2 Novai has generated approximately £5.5 million in revenue from pharmaceutical partnerships.
Unidentified speaker (speaker_1) · 39:54
Episode sections
- 0:00 – 2:46
Introduction and Technology Overview
Host introduces Novai and founder Francesca Cordeiro. Cordeiro explains DARC technology, which uses a fluorescent dye injected into the arm to label stressed cells in the eye, visible due to the eye's transparency. AI is used to detect these cells, which serve as early markers for disease activity.
- 2:46 – 8:41
AI Role and Clinical Validation
Cordeiro details how AI provides rigorous, repeatable detection of labeled cells, analyzes spatial patterns to hint at specific diseases, and classifies cell types. She notes the technology has been validated across 130 patients funded by the Wellcome Trust at UCL and Imperial College.
- 8:41 – 11:15
Commercialization and Pharma Interest
Novai formed just before the pandemic. Cordeiro explains that pharma companies were interested because DARC can determine drug efficacy in weeks during Phase 1/2 trials, allowing for 'fail fast' strategies. The technology is predictive of long-term outcomes compared to conventional measures.
- 11:15 – 17:39
Global Trials and AI Evolution
During the pandemic, trials moved to Australia with remote imaging and cloud-based AI analysis. Cordeiro discusses the shift from traditional algorithms to machine learning (CNNs) between 2020 and 2026, significantly improving specificity and sensitivity in cell detection.
- 17:39 – 23:35
Market Size and FDA Engagement
Cordeiro identifies a £60 billion market for geographic atrophy, a subset of macular degeneration. She describes a recent FDA meeting where regulators were excited about DARC's potential as a prognostic biomarker to identify patients who would benefit from expensive new treatments.
- 23:35 – 29:26
Funding, Validation, and Competition
Cordeiro highlights non-dilutive funding from Wellcome Trust, Innovate UK (nearly £6 million total), and Wealth Club. She contrasts Novai's single-cell level detection with competitors like Google DeepMind, which operates at a structural tissue level, noting Novai's proprietary database and USP.
- 29:26 – 34:16
Regulatory Pathway and Series A Plans
Novai is pre-Series A, seeking an extension after a recent FDA meeting. The upcoming pivotal trial in the US aims to get the intravenous dye approved and validate the AI. Cordeiro emphasizes the need for funding to bridge the gap to commercialization and Series A.
- 34:16 – 37:40
Future Vision: Nasal Spray and Global Screening
Cordeiro describes a nasal version of the dye, currently in preclinical studies, which would allow self-administration and high-street screening. She envisions a future where patients use iPhones for imaging, enabling global access to early diagnosis of eye and brain diseases, potentially within five years with Series A funding.
- 37:40 – 39:24
Prognostic capability and treatment pipeline
The speaker explains that the technology is currently prognostic, identifying patients who already have disease but are years away from vision loss. She notes that treatments for these neurodegenerative eye and brain diseases are either available or in development, with AI drug discovery expected to accelerate progress.
- 39:24 – 40:54
Team composition and early revenue
The speaker highlights the importance of a strong commercial, scientific, and clinical trial team. She states that the company has generated approximately £5.5 million in revenue from pharmaceutical partnerships and is conducting its first-ever patient dosing in a new clinical trial.
- 40:54 – 41:29
Mentorship and learning from others
The speaker advises entrepreneurs to recognize that challenges have likely been faced before and to learn from others' experiences rather than assuming they are the first to encounter a problem. She emphasizes humility and the value of understanding prior work in the field.
- 41:29 – 42:10
Inspiring next-generation entrepreneurs
The speaker confirms she is inspiring future clinical entrepreneurs through her involvement with PhD and medical students, as well as MSc students at institutions like Purpan and UCL, some of whom have become entrepreneurs themselves.
- 42:10 – 43:39
Personal routine and pivot strategy
The speaker shares that she skips breakfast, having a matcha latte instead, and eats lunch by 11:30 or 12:00. She identifies her pivot from glaucoma to macular degeneration as the most significant strategic shift for the company.
- 43:39 – 44:36
Commercialization motivation
The speaker describes the satisfaction of seeing a conceptual idea become a commercial reality that helps patients. She explains that she became an entrepreneur because academic funding alone was insufficient to bring the technology to patients.
Claims worth verifying
The DARC technology involves injecting a fluorescent dye into the arm to label stressed cells in the eye, which are then visualized due to the eye's transparency.
Unidentified speaker (speaker_1) ·2:13
How to verify: Check Novai's technical white papers or clinical trial protocols for the DARC mechanism of action and administration route. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The technology has been used in 130 patients funded by the Wellcome Trust at UCL and Imperial College, with no recorded side effects across 400 procedures.
Unidentified speaker (speaker_1) ·8:27
How to verify: Search Wellcome Trust grant databases for awards to Francesca Cordeiro/UCL/Imperial and review published clinical safety data for DARC. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceThe speaker uses a CNN (Convolutional Neural Network) for AI, noting significant improvements in specificity and sensitivity between 2020 and 2026.
Unidentified speaker (speaker_1) ·14:46
How to verify: Check Novai's AI methodology papers or technical documentation for model architecture and performance metrics over time. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The market for geographic atrophy, a subset of macular degeneration, is a £60 billion market.
Unidentified speaker (speaker_1) ·19:26
How to verify: Verify against healthcare market research reports on geographic atrophy treatment and diagnostic markets. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Novai had a meeting with the FDA a couple of months before the podcast (released Nov 2026), where regulators expressed excitement about DARC as a prognostic biomarker.
Unidentified speaker (speaker_1) ·19:56
How to verify: Check FDA correspondence records or Novai's press releases for dates of FDA meetings and outcomes. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Novai is pre-Series A and seeking a funding extension after the FDA meeting to optimize valuation before Series A.
Unidentified speaker (speaker_1) ·29:46
How to verify: Check Novai's cap table, investor updates, or filings with Companies House for equity rounds and valuation. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceA nasal version of the dye is in preclinical studies, funded by Innovate UK, aiming for self-administration and high-street screening.
Unidentified speaker (speaker_1) ·34:16
How to verify: Check Innovate UK grant details for nasal spray development and Novai's preclinical trial status reports. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The technology can identify patients with disease three to four years before it manifests as vision loss.
Unidentified speaker (speaker_1) ·37:40
How to verify: Check Novai's whitepapers or clinical trial publications for data on the lead time between biomarker detection and clinical symptom onset in glaucoma or macular degeneration cohorts. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Treatments for neurodegenerative eye and brain diseases are either currently used or in the pipeline, with AI drug discovery advancing rapidly.
Unidentified speaker (speaker_1) ·38:31
How to verify: Search clinical trial registries (e.g., ClinicalTrials.gov) for ongoing trials in neurodegenerative eye/brain diseases and review AI drug discovery company announcements (e.g., from Recursion, Insilico Medicine) for recent approvals or partnerships. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The company has generated approximately £5.5 million in revenue from working with pharmaceutical companies.
Unidentified speaker (speaker_1) ·39:54
How to verify: Review Novai's investor relations page or press releases for announcements of licensing deals or revenue recognition with pharma partners; check UK Companies House filings for revenue disclosures if publicly available. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceThe company is dosing its first patient in a new clinical trial.
Unidentified speaker (speaker_1) ·40:14
How to verify: Search ClinicalTrials.gov or the EU Clinical Trials Register for Novai's active trials and check for 'Recruitment status' updates or press releases confirming first patient dosed. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The speaker mentors PhD and medical students at Purpan and UCL.
Unidentified speaker (speaker_1) ·41:53
How to verify: Check faculty profiles or research group pages at Purpan (Toulouse) and UCL for Francesca Cordeiro's listed mentoring activities or collaborations. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceThe company's original focus was glaucoma before pivoting to macular degeneration.
Unidentified speaker (speaker_1) ·42:57
How to verify: Review Novai's historical press releases, website archive, or early scientific publications to confirm initial target indication was glaucoma. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The Wellcome Trust provided funding to the speaker.
Unidentified speaker (speaker_1) ·43:59
How to verify: Search the Wellcome Trust grant database for awards granted to Francesca Cordeiro or Novai prior to commercialization. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the £60 billion market size for geographic atrophy by reviewing market research reports from firms like Grand View Research or Evaluate MedTech.
- Check Novai's funding history and investor list on Crunchbase or PitchBook to confirm the £6 million from Innovate UK and Wellcome Trust.
- Review FDA meeting records or public summaries regarding Novai's engagement as a prognostic biomarker for geographic atrophy.
- Compare Novai's proprietary database and single-cell detection claims against public disclosures from competitors like Google DeepMind or other ophthalmic AI firms.
- Assess the clinical trial status of the US pivotal trial by checking ClinicalTrials.gov for Novai's study identifiers and recruitment status.
- Verify the £5.5 million revenue figure by reviewing Novai's financial statements or press releases regarding pharmaceutical partnerships.
- Investigate the regulatory pathway for the intravenous dye approval by reviewing FDA guidance on contrast agents and biomarkers.
- Check for conflicts of interest or biases in the Wellcome Trust and Innovate UK funding sources regarding their investment criteria and expectations.
Full transcriptexpand
0:00Unidentified speaker (UNKNOWN): Hello
0:00Unidentified speaker (speaker_0): and welcome to Founders and Funders from Wealth Club, the podcast exploring the stories behind successful entrepreneurs and also the investors helping those businesses grow. We're focusing today on Novi, which is a life sciences company which helps detect disease super early. There is the use of a really novel retinal biomarker alongside artificial. intelligence that is really the game changer. And I'm delighted to say that the founder, Francesca Cordero, is with me here in the Wealth Club studio.
0:43Unidentified speaker (speaker_1): I think it's the passion of trying to prevent patients going blind. Ability then to de-risk your investment, which is what your Wealth Club and your SFC angels are talking about, that thinks you will always need a clinician on a holistic type of assessment of a patient.
1:06Unidentified speaker (UNKNOWN): The
1:06Unidentified speaker (speaker_0): more you know,
1:07Unidentified speaker (speaker_1): the more you realise you don't.
1:09Unidentified speaker (speaker_0): I'm delighted to say that Francesca Cordero is with me here in the podcast studio. Great to have you with. me. Francesca, first of all, can you just explain the technology behind Novai, what you do, and when you discovered that this was such an opportunity for the world?
1:29Unidentified speaker (speaker_1): Well, thank you very much. Delighted to be here. The actual technology, just so that we can explain it, is dark. And it sounds DARK, but it's actually DARC. And it's really looking at the very earlier stage, a cell becomes stressed and therefore is a marker of disease activity. Now, the eye is the only place in the body that is transparent, so just as you are using your eye to look out, we can use that same way of looking to the transparent side of almost like a I like to call it a tissue culture plate of cells. So we have the capacity in the eye to look at these single cells. And the technology dark is really a way of fluorescently labeling labelling those cells through a die that you put into your arm. and I emphasize that it's not in the eye, it's into your arm, which then can be seen because
2:35Unidentified speaker (UNKNOWN): the
2:36Unidentified speaker (speaker_1): eye is transparent, through this picking up these uh cells that are stressed, and some of them are going into a process of cell suicide.
2:46Unidentified speaker (speaker_0): So you can use then artificial intelligence to heighten this. process and look even deeper and discover different diseases.
2:55Unidentified speaker (speaker_1): Absolutely, you've got it. Okay, I don't need to say anything else. Yeah, so the the issue is there are lots of cells in the retina. The retina comes from embryologically the same place as the brain. And actually, there are a lot of similarities with lots of cells around the body, but you can see these particular cells. in the eye much better than you could elsewhere. And the AI provides two or three things. One is a very quick and rigorous way of automatically picking up this cells that are that are labelled. So if you can imagine the night The sky, they look like sparkling stars, okay? But automatically picking up within seconds is something that it would be very difficult uh to do in a scaled up type of version. So that's the first thing. And it's rigorous as well. You you you have a repeatable and and really um when you're talking about AI, the nicest thing about it it is reliable. Okay, so the same salad cell it would count as being possible. positive, uh
4:05even a year apart, uh, would be definitively a positive signal, which would not be the case if you've got human error uh coming to bear. So that's number one. Number two is you're looking at the distribution, the pattern that these cells are lit up at the back of the eye. That can give you a real hint. of what disease process you're talking about. So it's not just one disease we can use this technique for, it's lots of diseases, eye diseases and brain diseases. And that spatial pattern is key to trying to say, oh yes, I think this patient is at risk of developing that. And the last thing is, and I mentioned this a few. seconds ago about their different cells that are in the retina, and they have similarities with the brain. The AI also allows us to look at the shape of those cells. And by doing that, it can tell us, ah, yeah, well, it's most likely to be this particular cell type which is associated with this particular disease. So it's that categorization and classification. that this whole application of AI allows us to do. But you can only do it because we have these cells already lit up with the technology.
5:24Unidentified speaker (speaker_0): How exciting was it when you kind of made this breakthrough and you looked at the potential for this? At what point did you think I do now have to become an entrepreneur?
5:36Unidentified speaker (speaker_1): So I don't think it was a sudden thing. Obviously. the first thing was uh excitement that we were picking up single cells, because nowhere else in the body has that been possible to do. Uh then the idea actually came because of the fact that we were routinely using this same protein to identify tissue culture cells that were dead or alive. So it wasn't wasn't my novelty of identifying this protein. It's something that had been there already. What was novel was applying a technique that is used in the lab directly into the patient and making use of that same translational element that is not possible elsewhere. So that moment. wasn't quite a eureka moment about an entrepreneur, but it was a eureka moment in saying this has great potential for applications to patients. And this is, you know, a personal um story as well, because obviously, being being a doctor, being a consultant, what was very, very sad
6:47was seeing these patients coming to see me in clinic, and these were majority type of glaucoma patients, because that's my speciality. And there was a heart sink moment when you'd thrown everything at them. They'd had um medicine, which is drops mainly, they'd had laser treatment, they'd even had surgery, but they were still losing vision. And one of the reasons this happens is because we discover the disease. far too late using conventional methods. So my aim had been well, if you could find these patients much earlier before they lose their vision, then they will never lose vision in the first place. And that was what drove me on to to look at these applications. Um And the entrepreneurship actually it I fell into. it and I probably shouldn't say that, but um I was very lucky that the Wellcome Trust, who have been funding me, you know, since 1996, um uh had this special
7:52type of grant uh which was for what we call translational type of project. So translational means bed bench
8:02Unidentified speaker (UNKNOWN): to bed.
8:02Unidentified speaker (speaker_1): bedside. So from the lab
8:06Unidentified speaker (UNKNOWN): to
8:07Unidentified speaker (speaker_1): the patient. And these are very expensive. It's high risk. Okay. So this is I got about four million pounds from them. But that was really the background to how Novi was formed because we'd already done, you know, 130 patients Um, with this technology, which had all been funded through the Wellcome Trust. And this uh was at UCL,
8:28Unidentified speaker (UNKNOWN): and
8:28Unidentified speaker (speaker_1): then the actual trials were done at Imperial. So all of this allowed us to already have quite a lot of validation in the technology before the actual um formation of Novi.
8:41Unidentified speaker (speaker_0): And you formed in the pandemic, at the time, it was just months, wasn't it, before one
8:47Unidentified speaker (UNKNOWN): month the
8:48Unidentified speaker (speaker_0): virus really hit? Yeah,
8:49Unidentified speaker (speaker_1): yeah, yeah.
8:50Unidentified speaker (speaker_0): When that happened. did you think, oh, this is just terrible timing? How are we gonna cope? How did you turn it around?
8:58Unidentified speaker (UNKNOWN): So
8:58Unidentified speaker (speaker_1): it's an interesting one because actually by that stage it was commercial. And um we had had a lot of interest from people wanting to work with it because obviously I'd been talking in conferences, um, and and people were aware this was really disruptive. This was doing something, you know, we can pick something up years before currently possible. And that particularly grabbed the imagination of pharma companies. So I'm sure you're aware that you know, if you're talking about the development of a drug, um, it possibly takes 10, ten, 15 fifteen years. often. A lot of that is due to the fact that when you get to the clinical stage, you have to wait two or three years before whether you know your drug has worked. Now, that is a very expensive, especially if there were hints that that drug probably wasn't going to be effective by the time you le get to phase three. And where we um sparked people's interest was in those early development stages, the phase one and the phase two, they're called. So when patients are first exposed to the drug, we were able to tell you in a matter of weeks whether your drug was working or not.
10:18So it was a huge type of proof of concept to the drug companies, but also what's also important to that is. you could fail fast. And people understand that. Failing fast means you're de-risking your drug development program. And you have a good translation of that in the fact that we were using all the time conventional measures, but the patients were having dark and then they are seen with conventional measures, you know, right up to 18 months, two years later. and in some cases three years later, showing that dark is predictive of those outcomes.
10:57Unidentified speaker (speaker_0): Francesca, thank you. We'd love you to subscribe to this podcast. Please go to wealthclub.co.uk forward slash podcasts. So you knew that there still was this huge appetite given how much interest that you received at all these conferences. When
11:15Unidentified speaker (UNKNOWN): you
11:15Unidentified speaker (speaker_0): couldn't see patients in this country during the pandemic, where did you go next? How could you start to really commercialize when the world had shut down?
11:24Unidentified speaker (speaker_1): Absolutely. Well, there was one country that was still doing clinical trials, um, which was Australia. And um the way we were able to function was we had to adapt very quickly to being able to uh get patients assessed and imaged by people on site in Australia, but we were remotely and virtually assessing them at the same time. And that was a huge change for us because until then, and I mentioned the Wellcome Trust, we'd had you know 130 patients, all those patients were done on one or two sites. So in the UK, all under controlled environments, this was different. This was we were teaching people how to image the patients. We were giving in real time feedback when they were imaging the patients. And then and and I suppose this is also where the AI comes into play because they then would upload the images onto the cloud, which is where we were able to do the analysis. So we you are absolutely right, we had to adapt very quickly. Um and you could say maybe it was for the best, because otherwise we'd have been limited in geography as to where we were doing the trials, but this meant that we had to be much more adventurous and and and go abroad, you know, Australia, despite the time differences, we
12:43managed to to to do that, yeah.
12:45Unidentified speaker (speaker_0): So you're up all night, were you?
12:47Unidentified speaker (speaker_1): Oh yes, I remember being up at two or three o'clock in the morning. um to coincide with the the the time when the patients were being imaged in Australia. Yeah.
12:56Unidentified speaker (speaker_0): And do you think then that has accelerated your access to other markets as well?
13:01Unidentified speaker (speaker_1): Um other markets meaning d different diseases or meaning differently. Geographic
13:06Unidentified speaker (UNKNOWN): geographies.
13:07Unidentified speaker (speaker_1): Oh yes, absolutely. So, you know, in in the US, which is where um I think um in our first application we will be going out to, we are doing trials in the the US, which possibly we wouldn't have even believed possible in 2020 when we started off. So absolutely, it did accelerate that.
13:28Unidentified speaker (speaker_0): We often hear about AI, the great strides that we've seen are going to be felt the most in healthcare. This is a real example of this, isn't it? Has it taken you by surprise the rapidity of the advance and how quickly it can be applied?
13:47Unidentified speaker (speaker_1): So interestingly, I think we were always aiming for an automatic way of trying to look at the dark signal. So before AI, you had algorithms, you know, things that people would now call AI. There were the very early stages of that. And when we first did our clinical trials in this country, that was what we were using. I think what has made me much more aware with rapidity of this field is the acceleration of the different ways you can do a simple task. So for example, identifying those cells as being stars in the night sky, an algorithm actually takes time to develop. With the AI, and I'm not talking about deep learning, I'm talking about machine learning here, so we use what's called a a CNN. You need a grand truth. We always had the grand truth, which was human observers. But the way you convert that grand truth to provide you
14:58a methodology for doing that automatic counting, that's changed dramatically, even from 2020 to where we are now, 26. You change and upgrade and use tools that come from the AI world, and it's a huge improvement. If you're looking at things when I talk about specificity and sensitivity, when you're getting a true positive spot or a false negative, those are the things that really gauge how good your AI is. And if you are comparing the different versions of Of what we've used over time, we've improved our ability. to get the correct count and the correct identification dramatically.
15:44Unidentified speaker (speaker_0): And you talk about that grand truth.
15:47Unidentified speaker (speaker_1): Yes.
15:48Unidentified speaker (speaker_0): How do you keep
15:49Unidentified speaker (UNKNOWN): the
15:49Unidentified speaker (speaker_0): clinician still right at the heart of all of these processes?
15:54Unidentified speaker (speaker_1): Well, the the clinician will never be completely at the moment, anyway. And I'm one of these people, being a medic myself, that thinks you will always need a clinician on a holistic uh type of assessment of a patient. So keeping the clinician uh in in the loop, I think is important in the stage we're in because we are never going to be, you know, you you have there are two ways of um doing diagnostic tools. Uh one is called a support tool, and one is actually decision maker. I don't think I want us yet to be in that decision maker. I want us to be a support tool where the clinician then decides: am I going to use what I'm gaining from the dark technology to help me decide which treatment I give my patient, whether I need to start treatment now, or whether I should switch treatments. Okay, so the clinician will. remain part of that decision making. It won't be taken away from them at all. And I mention holistic because one thing we're very good at as medics, and I'm yet to see the same thing simulated in an AI tool, is we can tell from like what a patient tells you historically, you know, I've had a
17:14vision. symptom or I've noticed my memory going or things aren't as clear as they used to be. It's not a yes-no checklist answer that an AI tool would would have to use. So there is an interpretation element from which we are using a lot of what we've been learnt over the years that AI at the moment does not have the capacity to do.
17:39Unidentified speaker (speaker_0): How large is your market? Why are health authorities and health trusts so excited about this technology?
17:46Unidentified speaker (speaker_1): So potentially our market is extremely large, and you would not believe me, so I'm not going to mention city numbers. So initially we are focusing on um macular degeneration. And not just um all of macular degeneration, even a subset of that. So a lot of people who who are aware of this disease will know in this disease which is associated with age, which is why it's getting more and more prevalent, because the aging population is rising, you lose your central vision. But there are two ways you have of losing that vision. One of them, you know, when I was at medical school, there was no way of treating macular degeneration at all. You would have a horrible conversation with a patient sitting opposite you saying, uh, you've got macular degeneration, I'm really sorry, but you you possibly go on to lose your vision and you won't be able to read anymore. You definitely won't be able to drive. But um
18:47ten years ago, a new treatment came in for what we call the wet form, which is new blood vessels leaking. More recently, there has been a new treatment in the other form of macular degeneration, which is geographic artery, which is incredibly exciting because it's opened the door for brand new treatments to be introduced that will stop these people losing their vision. But how they get to that stage. where they can be treated early enough, that is really being the challenge. So when you're talking about that market, and I'm only talking about this more recently treatable disease, which is called atrophy, geographic atrophy, that's a 60 billion pound market. And if you're talking about using dark um to first diagnose and pick up early diseases, disease or to monitor that disease, that actually is a lot of um
19:47vulgar pans,
19:49Unidentified speaker (speaker_0): a lot of potential. Yes. But it can be used then to detect other diseases in the body.
19:56Unidentified speaker (speaker_1): Absolutely. Absolutely. So um we had an amazing meeting with the FDA uh a a couple of months ago. So the FDA were extremely excited because there was an unmet need in America at the moment for two drugs that have just been available only in the US, where it's been shown that they can work, they have to be given early, but they are really expensive. And identifying which patients would benefit most is something that's a challenge. So, in other words, should you be using this drug on Mrs. Smith, I should have had an American name there, who has early signs of this disease, are they at risk of losing their vision? And this is what Doc DARC can provide. It provides a measure. of whether that patient is likely to lose that vision and therefore would benefit from this expensive treatment.
20:58As opposed to what could happen is you rely on conventional measures, but those patients are never going to lose their vision. And would you really use a lot of money on those patients? I don't think you would. You You'd want to do appropriate treatment and tailored to how that patient responds. So they were very excited that we could be used, and I'm going to use a a a technical term here, a prognostic biomarker. In other words, our ability to predict future disease in this type of macular degeneration, and we've published on this, these are scientific. papers that we've shown, would mean that we could be used to help appropriate medication being given to these patients.
21:49Unidentified speaker (speaker_0): How is it for you as a scientist clinician, though, to move from the lab doing your research to then trying try to lobby the Food and Drug Administration, trying to really progress the technology, trying to get more sales. That must be quite a challenge.
22:08Unidentified speaker (speaker_1): Tell me about it. Yes, my um both kids have said they uh will never be medics. Well, it's too late now. Neither of them are, unless they're gonna change. Um because I suppose you would call me a bit of a workaholic, but I'm I think it's the panic. passion of trying to prevent patients going blind, which really is how I got into this. Um, and the idea that it could now be used for other diseases beyond just the eye, you know, Alzheimer's, Parkinson's, multiple sclerosis, these are devastating conditions. And we've already got, you know, a good amount of evidence that this. could be helpful for those. Um, we had a Michael J. Fox Foundation Award, which is for Parkinson's. Uh, we've used a lot of Innovate UK money. So I mean, I actually would have to say we've been incredibly fortunate that Innovate UK have been supportive. I think we've almost had
23:11nearly six million pounds from them, uh, which has been incredibly. helpful because it's allowed us to do things that are not just business oriented, but going beyond that to these wider applications. So after G the geographic atrophy, we could go into the glaucoma, we could go on to inherited retinal diseases, and then we could go into the brain diseases.
23:35Unidentified speaker (UNKNOWN): So
23:35Unidentified speaker (speaker_0): the it's all these different sources of funding which have been really instrumental. in your growth. Tell me about the involvement with Wealth Club and how it all kind of ties in, getting that backing from the medical establishment and those initial grants and how that then helps uh you raise money from elsewhere.
23:54Unidentified speaker (speaker_1): Yeah, absolutely. So I think the the main thing to say about grant um funding is not only is it non non-dilutive, dilutive, but also it allows you to gain some validation. So the more validation you are have, so the fact that we've been used in almost 400 procedures of doc in in patients now is in itself important when you're talking to people like the regulatory authorities because it's been totally safe. We have no side effects that have been recorded in these 400 procedures, but also because we've published on a scientific level and we have had grants that um allow us to do that, that we have enough
24:41Unidentified speaker (UNKNOWN): um
24:43Unidentified speaker (speaker_1): recognition from established bodies that this works. It says what it you know does
24:49Unidentified speaker (speaker_0): on the 10.
24:49Unidentified speaker (speaker_1): Absolutely. Um and the ability then to de-risk your investment, which is what your wealth club and your SFC angels are talking about, becomes much better developed. Because you're not expecting these people to be specialists. I I I really get it, and I've probably said a lot of technical words, even though I've tried not to. This is a niche type of market, but the capacity. to change and disrupt the environment in health is is very big here. But it is unless you were aware of of this area, which obviously most people will not be, you would find it very risky. And all this non-dilutive funding does and allows you to show scientifically and and in clinically, that you have something, uh a product that works.
25:45Unidentified speaker (speaker_0): You have competitors though. I mean technology is moving so fast in so many different parts of the world, in labs globally, uh similar techniques are being developed. Do you can do you worry about that, the fact that or do you actually see this as a kind of holistic progress? that you're making?
26:04Unidentified speaker (speaker_1): So at the moment, there isn't a technology that can identify sick health or healthy cells at a single cell level. That's really our USP. The other thing is we've been doing this for a while now. So we have actually a a proprietary database. You know, nobody else can s have as many. types of images as us. AI is being used obviously in ophthalmology. You would have read, you know, Google DeepMind started working with the eye through routine retinal imaging that Spec Savers offers, but it's not at a cellular level. It is on a structural level, which means the tissue has to change its formation, but you cannot see single cells with it. So the AI world in ophthalmology, you could say, was a competitor because you're talking about very large databases of easily acquired images, but they don't have that unique ability to look at single cells. And I think where we are different.
27:15is because we provide a snapshot of disease activity where you can with good treatment, you can even use our technology to show that it's worked, okay, at a single cell level, before you have your tissue shrinking, which is what the the the retinal images currently do. They are looking for changes in in structures, what we we'd call it, in the tissue. We are looking before that, and that's you know, quite a few years before. So um it's a different thing altogether. And and um I think testament to that is when when I went to the FDA a couple of months ago, there are almost 30 FDA representatives in there. Now, in all my years, I've never seen that. type of large um sort of representation. And the reason is they weren't sure which section we belong to. Because, you know, on one hand we're imaging, on another hand, um
28:15we're ophthalmology, on another hand, we're using a biologic. So we are doing something very different, and there's good and bad associated with that, as you can imagine, um, because you're having to doing something disruptive is you are setting new standards and you are having to beat your pathway because it hasn't there's no precedent.
28:37Unidentified speaker (speaker_0): And that must be quite challenging. Do you sometimes think do you sometimes get just very frustrated?
28:42Unidentified speaker (speaker_1): I think um I would be superhuman not to.
28:48Unidentified speaker (speaker_0): Okay.
28:49Unidentified speaker (speaker_1): Like the rest of us, I well, I think maybe not the rest of us, but I would have wanted everything done yesterday. Um my very first paper on this technology actually said this will translate to humans soon in a matter of years. Uh it's been at least, I mean not quite two decades, but it's been that amount of time, right? Um and so I do get frustrated at that, and and funding, obviously. So Wealth Club is an example, SFC, an example, have been very supportive. Um we are keen to get an extension of our funding that Wealth Club came in. I think we got Wealth Club for the first time involved in April this year. Uh we're going back in just an extension of the round because now we've had that FDA meeting. We really want to make sure that we can optimize our valuation before we do Series A. So we're still sort of that pre-Series A route. And this has been a huge type of inflection point for us, the FDA recognition. And that will have the fact that we have this pathway. uh very neatly put out here. Um the
30:06Wealth Club money came in actually as part of that, getting our regulatory uh pathway straight. Um, but it is important that we always have funding. And I think if you talk to most fans, that's the biggest issue is to make sure that your funding allows you to do quickly or quicker. stuff that you would not normally be have an ability to do.
30:30Unidentified speaker (UNKNOWN): Thank you.
30:31Unidentified speaker (speaker_0): If you want to find out more about single company investments via Wealth Club, please go to wealthclub.co.uk forward slash single company. So that is your the first destination on your roadmap ahead, is trying to crack uh the US market, then.
30:47Unidentified speaker (UNKNOWN): I
30:47Unidentified speaker (speaker_1): think so. And we've you know, if we we have to do a pivotal trial which has more American patients in them. But that serves two purposes for us. One is to get the intravenous dye approved for use in patients. Second it will allow us to validate our AI. So it's killing two birds with one stone. And and that obviously is is of huge value because moving on to being that support tool,
31:18Unidentified speaker (UNKNOWN): being
31:18Unidentified speaker (speaker_1): used in clinics because at the moment we've just been used in clinical trials, actually helping patients much in a way that we know that the clinicians really want us to is only possible if we can be used in in clinic, in hospitals in in in uh private rooms around the world.
31:36Unidentified speaker (speaker_0): How would you say uh this sums up? the innovation that is within British universities and institutions? Your the development of of your research into this enterprise that is going global. What does it say about the level of research that is and and how much expertise there currently is in the UK?
32:00Unidentified speaker (speaker_1): So I think on a scientific level and even on a clinical level, we are extremely ahead of the game. I'm not sure whether that goes through to commercialization. So let me first talk about the science. I think things like The Wellcome Trust, Innovate UK are unique and they really are keen to promote innovative. research. So that type of recognition and support network that you have in this country, I think, is incredibly important. I'm very fortunate because I'm two big universities here. I'm chair of ophthalmology at Imperial College, I'm also a professor at UCL. And it's worked synergistically, also being the director of the Clinical Trials Unit. This has been quite helpful because obviously all of them have been involved in in this area. And that support is also very unusual, I think. In in most places around the world, the basic science, the translation to clinic, um and the ability to also work commercially um i i is very uh good. Where I think
33:17Unidentified speaker (UNKNOWN): um
33:19Unidentified speaker (speaker_1): there needs to be a bit more investment is that next stage, which is, you know, where a lot of companies fail, and if you I'm sure you're aware, is um cross that gap, bridging that gap. And you know, it's where we are in in terms of a lot of companies not being able to go to that Series A stage because of the investment. Obviously, Wealth Club, obviously, you know, um, a lot of support that we've had through our our our angels uh has helped dramatically get to that next stage. But it still is a gap. Um, and I am Um lucky with our non-dilutive funding. I mean, we've just had an in our sovereign AI um type of reach from Innovate UK, we just had a million pounds. And that helps us, you know, you were talking about the AI, that's really helped us with the AI stuff. But in terms of giving us more, because the more funding you have, the faster you can move. And funding has been a delay to to me personally, I think. I think um I obviously I would have wanted to walk yesterday. Uh uh but Rena
34:32Unidentified speaker (speaker_0): Marathon.
34:32Unidentified speaker (speaker_1): Absolutely. Um but even taking that into account, you know, we haven't talked about I I've mentioned the intravenous, but we've also developed a nasal version. And that means that it'll be easily used and accessible on the high street, because the patient can self-administer self administer it and then they go in. and have a test of the screening service or uh a techno a technician can do it. It doesn't have to be in a hospital. That changes the game completely because it means it'll be something that could be used as a screening test for eye and brain disease. And that's huge. But to do that you need money and the money at the moment we're only doing the tried and test tested route, which is um geographic atrophy, intravenous use. Ultimately, what I would love is to say that um you can use your iPhone in the middle of India or Africa to capture an image of the back of the eye, and it's not science fiction, you can already do things um for eye examinations with your iPhone. Um, uh with the patient being clearly um self-administering the nasal spray, and then that gets beamed for an AI interpretation, and you would say, this patient is normal, abnormal, this patient is highly
35:52likely to have this disease. They should be either seeing a neurologist or uh an ophthalmologist as soon as possible. And that will completely change. the landscape.
36:04Unidentified speaker (speaker_0): How far away do you think we are from that?
36:07Unidentified speaker (speaker_1): Money is the thing, right? So if we were to go to Series A and say, as part of series A, uh we want to develop the screening part, um, then we'd have to ask for more money. Uh and uh that would be, you know, five years.
36:22Unidentified speaker (UNKNOWN): You
36:22Unidentified speaker (speaker_1): know, we're using that just to give you an idea. The nasal version we did have a um funded through another Innovate UK grant. So we've gone so far, and we're using it routinely in our preclinical studies. So that shows you that it works pretty well. It's just the next stage is is just uh manufacturing it for the patient.
36:45Unidentified speaker (speaker_0): So so much potential ahead. You mentioned mention your children don't want to enter the medical. profession, but they must be super proud of what you've achieved. And
36:55Unidentified speaker (UNKNOWN): oh
36:55Unidentified speaker (speaker_1): yeah, I mean it's a very supportive family I have, my husband in particular. But they also see they see the ups and the downs. And you've mentioned the frustrations, and you know, I definitely have been frustrated. But I am in a unique position. Not many clinicians can say they've seen something they've taken from concept right up to sort of patient benefit.
37:21Unidentified speaker (speaker_0): And how satisfying is it when you know you've diagnosed a condition very early, and that obviously the patients themselves will probably not be too happy about getting that diagnosis, but from your point of view, it must be really. fulfilling.
37:40Unidentified speaker (speaker_1): So at the moment, I don't think I could say that we've had the ability to definitely diagnose because the way the the system works is the reason why we were prognostic is because the patient already has disease. But what we've shown is if they have disease, it can take three to four years before it manifests towards something that's going. to threaten vision loss. And so we can already identify those patients well ahead of time. And that is satisfying. As long as you have a treatment. And so all these diseases I'm talking about, which dark has an application to, there are treatments, if not already being used, in the pipeline. And all these areas of neurodegeneration in the eye and and in the brain do have huge pipelines of treatments coming through. It's all very exciting. Again, you will be fully aware of AI drug drug discovery. I mean, that's been a big um area of focus in this country actually. How to use AI to get new drug targets and new designed drugs. And I'm sure this field is going to advance.
38:51very, very quickly. Having a drug that you know is going to work will mean that that disease is treatable. And the earlier you can treat that patient, they never have to lose their memory, they never have to develop a tremor. And of course for me, they never have to even have a slight reduction in their vision. And that's the aim. That's, you know, that's my my dream.
39:15Unidentified speaker (speaker_0): You have had all these frustrations, but how do you build a team around you to help you deal with them and just keep forging that path?
39:24Unidentified speaker (UNKNOWN): Uh
39:24Unidentified speaker (speaker_1): well, the team is really important. Um, the team commercially has been extremely impressive. They're There. people if if you work for a startup, I think by definition. you're already knowing that you're doing something different. And that obviously there are peaks and troughs, but you're in it for the long haul, hopefully. And you know, our data scientists are great. We have an amazing team of scientists and RD. R D. And we have early commercial revenues, you know, we've had about five and a half million. in revenue from working with pharma companies. The team in the hospital and my clinical trial unit are paramount because obviously you don't get patients coming through doing clinical trials. I mean, at the moment, I'm I I'm really sorry that I had got my times wrong. Um, because we're doing a brand new clinical trial at the moment, uh Our first patient ever in the world is being. dosed. This is another type of baby of mine. But that's only possible if you
40:34have that infrastructure and that support. And then finally, the basic science and um and and the laboratory science is key that everyone is excited. And you know, people forget that in science you can have good days and you can have bad days. but it's learning from your mistakes. Um, one of the things I always tell
40:57Unidentified speaker (UNKNOWN): when
40:57Unidentified speaker (speaker_1): I'm mentoring people is
41:01Unidentified speaker (UNKNOWN): the
41:01Unidentified speaker (speaker_1): more you know, the more you realise you don't. Um, I think it's only those rather when you're younger and you're a little bit arrogant, you don't realise Realize that someone's probably already thought about it or that this is this challenge may have come before. Um, you think that oh, this is this is me, I'm first time, I'm able to do it at all. But that's not quite the case. People usually have already been there before, and there is so much to learn from what other people have have done uh before you.
41:29Unidentified speaker (UNKNOWN): Have
41:29Unidentified speaker (speaker_0): you got any evidence that you are starting to inspire the kind of next generation of clinical entrepreneurs within your universities? You talk about the
41:37Unidentified speaker (UNKNOWN): it. city. Oh, yes, yes, absolutely.
41:39Unidentified speaker (speaker_1): So I hate to think how many PhD students I have. But absolutely, it's not just PhD students, medical students, in the type of MSc stage that people do their thesis, their mini-thesis mini thesis in Pural Puron and UCL. Um I've can to name you several. who've gone on to uh become entrepreneurs in their own right.
42:07Unidentified speaker (speaker_0): Fantastic.
42:08Unidentified speaker (UNKNOWN): I've got
42:09Unidentified speaker (speaker_0): a few quick fire questions just
42:10Unidentified speaker (UNKNOWN): before we
42:10Unidentified speaker (speaker_0): end. Yeah. You're a very busy woman. Do you have time for breakfast? And if so, what do you have?
42:16Unidentified speaker (speaker_1): I don't have time for breakfast, which is a bad thing. So by eleven thirty, twelve I will normally have uh an early lunch. However one of the things I've been doing is having um a a matchelate um first thing in the morning, which seems to make a a a big difference to my day.
42:35Unidentified speaker (UNKNOWN): Makes
42:36Unidentified speaker (speaker_0): it much more pleasurable. Okay, and if there was one thing that you wish you'd known when you set off on your journey, what would it be?
42:44Unidentified speaker (speaker_1): I think um it would be the the ideas of the um learn from your mistakes and pivot. I think that's my key really.
42:55Unidentified speaker (speaker_0): How did you pivot?
42:57Unidentified speaker (speaker_1): So we've mentioned macular degeneration. My original plan was to do glaucoma. Okay, so that that's one pivot. Um and I think uh I've I've had other pivots along the way, um, but that's probably the the biggest one for the company.
43:14Unidentified speaker (speaker_0): Also? which app on your phone could you not do without?
43:18Unidentified speaker (speaker_1): News. Easy News.
43:21Unidentified speaker (speaker_0): Big fan. And what do you think you'd like to tell founders, other founders, other entrepreneurs setting off on those on their journeys? What one secret would you like to convey or or one tip that could really help them?
43:39Unidentified speaker (speaker_1): The satisfaction you get from seeing your conceptualized idea mature into a commercial feat. In my case, it meant allowing us to go to patients. Um, and you know, you asked me how did I flip to being an entrepreneur? It was the only way I could get this to the patient. The the Welcome Trust funding was only so far. So I would say there is a huge satisfaction, and don't forget that, in seeing your idea materialize into something commercial that's going to help people.
44:15Unidentified speaker (speaker_0): Fantastic. Well, it's been wonderful to have you on the podcast, Francesca. Thank you so much. Pleasure. And good luck with the rest of the journey.
44:22Unidentified speaker (speaker_1): Thank you.
44:23Unidentified speaker (speaker_0): And thank you as well for listening to this episode. If you want to subscribe, please go to wealthclub.co.uk forward slash podcasts.